Selicrelumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, selicrelumab targets and binds to CD40 expressed on a variety of immune cell types. This induces CD40-dependent signaling pathways and triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced anti-tumor immune response. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it plays a key role in the activation of the immune system.

**Synonyms:** - CD40 Agonist Monoclonal Antibody CP-870,893 - CP-870,893 - RO7009789 - SELICRELUMAB